Commentary on: The optimal Dose of Ribavirin for Chronic Hepatitis C: From Literature Evidence to Clinical Practice

authors:

avatar Mortada El-Shabrawi 1 , * , avatar Mona Isa 1

Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt
Hepatitis Monthly: Vol.13, issue 2; e7867
published online: February 28, 2013
article type: Letter
received: August 22, 2012
accepted: September 22, 2012
DOI: https://doi.org/10.5812/hepatmon.7867

how to cite: El-Shabrawi M, Isa M. Commentary on: The optimal Dose of Ribavirin for Chronic Hepatitis C: From Literature Evidence to Clinical Practice. Hepat Mon. 2013;13(2):e7867. https://doi.org/10.5812/hepatmon.7867.

References

  • 1.

    Abenavoli L, Mazza M, Almasio PL. The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C. Hepat Mon. 2011;11(4):240-6. [PubMed ID: 22087150].

  • 2.

    Poynard Thierry, Yuen Man-Fung, Ratzin Vlad, Lai Ching Lung. Viral hepatitis C. The Lancet. 2003;362(9401):2095-100. https://doi.org/10.1016/S0140-6736(03)15109-4.

  • 3.

    Abonyi ME, Lakatos PL. Ribavirin in the treatment of hepatitis C. Anticancer Res. 2005;25(2B):1315-20. [PubMed ID: 15865084].

  • 4.

    Weber George, Shen Fei, Prajda Noemi, Abonyi Margit. Down-regulation by drugs of the increased signal transduction in cancer cells. Advances in Enzyme Regulation. 2000;40(1):19-34. https://doi.org/10.1016/S0065-2571(99)00039-4.

  • 5.

    Jamall IS, Yusuf S, Azhar M, Jamall S. Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3? World J Gastroenterol. 2008;14(43):6627-31. [PubMed ID: 19034963].

  • 6.

    Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40(6):993-9. [PubMed ID: 15158341]. https://doi.org/10.1016/j.jhep.2004.02.007.

  • 7.

    Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003;38(3):639-44. [PubMed ID: 12939590]. https://doi.org/10.1053/jhep.2003.50350.

  • 8.

    Bjoro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol. 2002;37(2):226-32. [PubMed ID: 11843062].

  • 9.

    Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40(3):484-90. [PubMed ID: 15123364]. https://doi.org/10.1016/j.jhep.2003.11.004.

  • 10.

    Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38(1):75-85. [PubMed ID: 12829989]. https://doi.org/10.1053/jhep.2003.50267.

  • 11.

    Patel K, McHutchison JG. Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. Cleve Clin J Med. 2004;71 Suppl 3:S8-12. [PubMed ID: 15468611].

  • 12.

    Saleem N, Mubarik A, Qureshi AH, Siddiq M, Ahmad M, Afzal S, et al. Is there a correlation between degree of viremia and liver histology in chronic hepatitis C? J Pak Med Assoc. 2004;54(9):476-9. [PubMed ID: 15518372].

  • 13.

    Sikorska K, Stalke P, Izycka-Swieszewska E, Romanowski T, Bielawski KP. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C. Med Sci Monit. 2010;16(3):CR137-43. [PubMed ID: 20190684].

  • 14.

    Sokal EM, Bourgois A, Stephenne X, Silveira T, Porta G, Gardovska D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol. 2010;52(6):827-31. [PubMed ID: 20400194]. https://doi.org/10.1016/j.jhep.2010.01.028.

  • 15.

    Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol. 2010;52(4):501-7. [PubMed ID: 20189674]. https://doi.org/10.1016/j.jhep.2010.01.016.

  • 16.

    Karnsakul W, Alford MK, Schwarz KB. Managing pediatric hepatitis C: current and emerging treatment options. Ther Clin Risk Manag. 2009;2009(5):651-60.